Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04922645 · ClinicalTrials.gov registry record · Phase 4
Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants
A Phase 4 study, sponsored by USRC Kidney Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 214
- Enrollment target
NCT04922645 is a Phase 4 study that has completed, run by USRC Kidney Research. The registered enrollment target is 214 participants.
The verdict
NCT04922645, a Phase 4 study, has completed, sponsored by USRC Kidney Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 214 participants
- Enrollment target
Study Summary
This study is being conducted to demonstrate the effect of Auryxia, when used as the primary phosphate lowering therapy, on the overall cumulative use of erythropoiesis-stimulating agent and intravenous iron as well as on the laboratory parameters indicative of phosphate and anemia management.
Interventions
- DRUG Ferric Citrate 1 gram Oral Tablet
- DRUG Standard of care phosphate-lowering therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2022-09-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04922645
The ClinicalTrials.gov registry entry for NCT04922645 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is USRC Kidney Research, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferric Citrate 1 gram Oral Tablet is the first listed.
NCT04922645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04922645 about?
NCT04922645 is a clinical study titled "Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants". This study is being conducted to demonstrate the effect of Auryxia, when used as the primary phosphate lowering therapy, on the overall cumulative use of erythropoiesis-stimulating agent and intravenous iron as well as on the laboratory parameters indicative of phosphate and anemia management.
What is the current status of trial NCT04922645?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 214 participants. The study started on 2021-06-29. Estimated completion is 2022-09-15.
What interventions are being tested in trial NCT04922645?
The interventions under investigation include: Ferric Citrate 1 gram Oral Tablet (DRUG), Standard of care phosphate-lowering therapy (DRUG).
Who is sponsoring clinical trial NCT04922645?
This trial is sponsored by USRC Kidney Research, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.